26 August 2015
Vol 7, Issue 302
  • Contents

    • Editorial

      • Trauma research—A field without a home base

        Trauma research can be a cost-effective investment worthy of attention and emphasis from the U.S. National Institutes of Health.

    • Focus

    • Research Articles

      • Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer

        Noninvasive mutation tracking in plasma can detect circulating tumor DNA arising from residual micrometastatic disease and thus identify patients at high risk of recurrence.

      • Pronounced species divergence in corticospinal tract reorganization and functional recovery after lateralized spinal cord injury favors primates

        Fundamental differences in the anatomy and function of the corticospinal tract support enhanced recovery of leg and hand function after lateralized spinal cord injury in primates compared to rodents, emphasizing the importance of primate models for spinal cord repair therapies.

      • IgH sequences in common variable immune deficiency reveal altered B cell development and selection

        Deep sequence analysis of the IgH repertoires of common variable immune deficiency patients highlights phenotypic features of the disorder and potential disease mechanisms.

      • A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo

        Targeting DLL3 with an antibody-drug conjugate eliminates tumor-initiating cells in high-grade pulmonary neuroendocrine cancers.

    • Editors' Choice

      • Inheritance of fear and trauma

        Holocaust survivors and their adult offspring show differences in DNA methylation, indicating that the effects of trauma can be passed down from human parents to their offspring.

      • Fight fire with fire

        A new drug kills cancer cells by hyperactivating oncogenes.

      • A soothing MSC-based ulcer treatment

        Targeting MSCs to regions of the gut containing ulcers enables mucosal healing in a VEGF-dependent manner.

    • Podcast

About The Cover

Cover image expansion

ONLINE COVER Liquid Biopsy. Circulating tumor DNA (ctDNA) can be captured from a simple, minimally invasive blood draw and then analyzed to understand a patient's disease. In this issue, Garcia-Murillas et al. show that tracking ctDNA mutations over time can tell breast cancer patients if they are at risk of relapse—some nearly 1 year before the cancer comes back—and what drugs might work best. Such early detection and prediction could change the way doctors care for their patients and plan personalized treatment regimens. See the related Focus by Sundaresan and Haber. [CREDIT: T. YURCHENKO/SHUTTERSTOCK]